Cargando…

Safety and efficacy of newer biologics DMARDs in the management of rheumatoid arthritis: A systematic review

OBJECTIVE: To analyze the safety and efficacy of certain biologics DMARDs (Adalimumab, Baricitinib, Pefacitinib and Sirukumab) either used alone or as a combination with MTX for management of rheumatoid arthritis. METHOD: We conducted a systematic literature review on various phase 3 Randomized cont...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zago, Basiru Ahmad, Priyadharshini, A., Vijayakumar, T.M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	REVIEW
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718147/ https://www.ncbi.nlm.nih.gov/pubmed/36474893 http://dx.doi.org/10.1016/j.ocarto.2020.100116

Ejemplares similares

Treatment of Rheumatoid Arthritis with Biologic DMARDS (Rituximab and Etanercept)
por: Gashi, Afrim A., et al.
Publicado: (2014)

Multidrug resistance proteins and DMARD efficacy in rheumatoid arthritis
por: Jansen, G, et al.
Publicado: (2004)

Biologic DMARDs and targeted synthetic DMARDs and the risk of all-cause mortality in rheumatoid arthritis: A systematic review and meta-analysis
por: Pang, Mengduan, et al.
Publicado: (2022)

Comparison of the efficacy and safety indicators of DMARDs for rheumatoid arthritis: A network meta-analysis
por: Wang, Zunlian, et al.
Publicado: (2021)

Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2023)

Assessment of prescribing pattern and adverse drug reaction in patients receiving anticoagulant therapy: A prospective observational study
por: Vijayakumar, Thangavel Mahalingam, et al.
Publicado: (2023)

Biomarkers to Predict DMARDs Efficacy and Adverse Effect in Rheumatoid Arthritis
por: Wei, Kai, et al.
Publicado: (2022)

Review of Eight Pharmacoeconomic Studies of the Value of Biologic DMARDs Adalimumab, Etanercept, and Infliximab) in the Management of Rheumatoid Arthritis
por: Doan, Quan V., et al.
Publicado: (2006)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
por: Mysler, Eduardo, et al.
Publicado: (2021)

COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs
por: Tsai, Jih-Jin, et al.
Publicado: (2023)

Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs
por: Rigby, William F. C., et al.
Publicado: (2017)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
por: Prawjaeng, Juthamas, et al.
Publicado: (2023)

Delayed conventional DMARDs therapy is effective in Rheumatoid Arthritis
por: Ahsan, Tasnim, et al.
Publicado: (2017)

Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
por: Riley, Thomas R, et al.
Publicado: (2021)

The Efficacy and Safety of Mainstream Medications for Patients With cDMARD-Naïve Rheumatoid Arthritis: A Network Meta-Analysis
por: Cai, Weiyan, et al.
Publicado: (2018)

The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs
por: Cho, Soo-Kyung, et al.
Publicado: (2017)

Prediction of sustained biologic and targeted synthetic DMARD-free remission in rheumatoid arthritis patients
por: Burkard, Theresa, et al.
Publicado: (2021)

Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients
por: Karadeniz, Hazan, et al.
Publicado: (2022)

Rheumatoid Arthritis and Malignancy: What Should We Do With DMARDs?
por: Jeon, Chan Hong
Publicado: (2022)

Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
por: Bhushan, Vandana, et al.
Publicado: (2021)

Trajectories of fatigue in actively treated patients with established rheumatoid arthritis starting biologic DMARD therapy
por: Provan, Sella Aarrestad, et al.
Publicado: (2020)

Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors
por: Terslev, L, et al.
Publicado: (2022)

bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search
por: Verhoef, Lise M., et al.
Publicado: (2017)

A comparative study of the efficacy of Chinese herbal medicine Duhuo Jisheng decoction combined with DMARDs vs isolated DMARDs for rheumatoid arthritis: A protocol for systematic review and meta analysis
por: Zhou, Xing, et al.
Publicado: (2020)

Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis
por: Verstappen, M., et al.
Publicado: (2020)

Intensive Intervention Can Lead to a Treatment Holiday from Biological DMARDs in Patients with Rheumatoid Arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2014)

Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis
por: Richter, A, et al.
Publicado: (2016)

Real World Experience of Disease Activity in Patients With Rheumatoid Arthritis and Response to Treatment With Varios Biologic DMARDs
por: Boyadzhieva, Vladimira, et al.
Publicado: (2018)

Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission with Six Months of Biological DMARDs Treatment
por: Miwa, Yusuke, et al.
Publicado: (2017)

Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)
por: Adami, Giovanni, et al.
Publicado: (2023)

Patient groups in Rheumatoid arthritis identified by deep learning respond differently to biologic or targeted synthetic DMARDs
por: Kalweit, Maria, et al.
Publicado: (2023)

The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis
por: Cutolo, Maurizio, et al.
Publicado: (2014)

Healthcare professionals’ perceptions on barriers and facilitators to DMARD use in rheumatoid arthritis
por: Voshaar, M. J. H., et al.
Publicado: (2022)

Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients
por: Nathalie, Luurssen-Masurel, et al.
Publicado: (2021)

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1
por: Coates, Laura C, et al.
Publicado: (2017)

Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry
por: Olsen, Inge C, et al.
Publicado: (2019)

The impact of bDMARDs on postoperative complications in patients with rheumatoid arthritis: A systematic review and meta-analysis
por: Suto, Takahito, et al.
Publicado: (2023)

Efficacy of non-conventional synthetic DMARDs for patients with rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis
por: Yuan, Haoming, et al.
Publicado: (2023)

The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study
por: An, Yuan, et al.
Publicado: (2016)

Study of the natural course and specific immunity after herpes zoster in patients with rheumatoid arthritis receiving biologic DMARDs
por: Thomas, Konstantinos, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_28nh6lfstump0lkdsl5j671tev